LeukoCatch, a quick and efficient tool for the preparation of leukocyte extracts from blood

BMC Clinical Pathology

Hiroshi Nojima⁴  Toshinari Ohmine³  Norikazu Yabuta¹  Shoichi Kimura²  Daisuke Okuzaki⁴ 

[1] Department of Molecular Genetics, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan;Fukae Kasei Co., Ltd., 3-2-44 Takatsuka-dai, Nishi-ku, Kobe, Hyogo 651-2271, Japan;Laboratory for Clinical Investigation, Osaka University Hospital, Osaka University, 2-15 Yamadaoka, Suita, Osaka 565-0871, Japan;DNA-chip Development Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan

关键词: proteomics;    PBMC;    diagnosis;    leukocyte;    cell extract;   

Others  :  1085577
DOI  :  10.1186/1472-6890-11-9

 received in 2011-05-06, accepted in 2011-08-17,  发布年份 2011

【 摘 要 】

Background

Whole-protein extracts from peripheral blood leukocytes are ideal for basic and clinical research. However, lack of a simple preparation technique has limited the use of such extracts. The aim of this study is to develop a simple and easy system that can selectively obtain leukocyte extracts without hemoglobin.

Methods

A filter that captures the leukocytes but not RBCs was set at the bottom of a 10-mL medical syringe by sandwiching it between plastic stoppers. The capturing efficiency of leukocytes with this tool, called LeukoCatch, was examined using human macrophage cells (MONO-MAC-6). The abilities of LeukoCatch system to capture the leukocyte proteins and to remove the hemoglobin from RBCs were tested by western blot analysis using human blood samples.

Results

This study presents the development of LeukoCatch, a novel tool that allows the preparation of leukocyte extracts from blood samples within 3 min without centrifugation. Tissue-cultured human macrophage cells were tested to determine the optimal filter numbers and pass-through frequencies of LeukoCatch, which was then applied to 2-mL blood samples. Samples were passed 2~5 times through a LeukoCatch equipped with 5 filters, washed twice with phosphate-buffered saline for red cell removal, and leukocyte proteins were extracted with 0.5 mL of elution buffer. Western blot analysis of the purified extract indicated that more than 90% of hemoglobin was removed by the LeukoCatch and that the protein recovery rate of leukocytes was at least 4 times better than that of the conventional centrifugation method.

Conclusion

We conclude that LeukoCatch is useful not only for diagnosis at the bedside but also for basic research using blood samples or tissue culture cells.

【 授权许可】

   
2011 Okuzaki et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Shalon D, Smith SJ, Brown PO: A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 1996, 6:639-645.
• [2]Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270:467-470.
• [3]Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
• [4]Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800.
• [5]Pascual V, Chaussabel D, Banchereau J: A genomic approach to human autoimmune diseases. Annu Rev Immunol 2010, 28:535-571.
• [6]Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63.
• [7]Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
• [8]Nakamura N, Shimaoka Y, Tougan T, Onda H, Okuzaki D, Zhao H, Fujimori A, Yabuta N, Nagamori I, Tanigawa A, Sato J, Oda T, Hayashida K, Suzuki R, Yukioka M, Nojima H, Ochi T: Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients. DNA Res 2006, 13:169-183.
• [9]Kobayashi S, Ito A, Okuzaki D, Onda H, Yabuta N, Nagamori I, Suzuki K, Hashimoto H, Nojima H: Expression profiling of PBMC-based diagnostic gene markers isolated from vasculitis patients. DNA Res 2008, 15:253-265.
• [10]Bauer JW, Bilgic H, Baechler EC: Gene-expression profiling in rheumatic disease: tools and therapeutic potential. Nat Rev Rheumatol 2009, 5:257-65.
• [11]Bøyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21 Suppl 1968, 97:77-89. (Paper IV)
• [12]Dzik S: Leukodepletion blood filters: filter design and mechanisms of leukocyte removal. Transfus Med Rev 1993, 7:65-77.
• [13]Ferrer F, Rivera J, Corral J, González-Conejero R, Vicente V: Evaluation of leukocyte-depleted platelet concentrates obtained by in-line filtration. Vox Sang 2000, 78:235-241.
• [14]Mascaretti L, Baggi L, Riva M, Proserpio P, Dassi M, Varallo F, Sciorelli G, Quarti C: Lymphocyte subsets in inline filtered packed red blood cell units: comparison between low and high spin procedures. Transfus Apher Sci 2002, 26:167-174.
• [15]Garred P, Honoré C, Ma YJ, Munthe-Fog L, Hummelshøj T: MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol 2009, 46:2737-2744.
• [16]Peri F, Piazza M, Calabrese V, Damore G, Cighetti R: Exploring the LPS/TLR4 signal pathway with small molecules. Biochem Soc Trans 2010, 38:1390-1395.
• [17]Hu X, Wohler JE, Dugger KJ, Barnum SR: Beta2-integrins in demyelinating disease: not adhering to the paradigm. J Leukoc Biol 2010, 87:397-403.
• [18]Saunders C, Herbert P, Rowe G, Hayward M, Wilkins K, Milligan J, Stenning M, Seacombe A, Prowse C: In-vitro evaluation of the PALL Leukotrap Affinity Prion Reduction Filter as a secondary device following primary leucoreduction. Vox Sang 2005, 89:220-228.
• [19]Sowemimo-Coker SO, Pesci S, Andrade F, Kim A, Kascsak RB, Kascsak RJ, Meeker C, Carp R: Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates. Vox Sang 2006, 90:265-275.
• [20]Longley RE, Stewart D: Recovery of functional human lymphocytes from Leukotrap filters. J Immunol Methods 1989, 121:33-38.